Treating HR+/HER2− breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression - Yeo, Winnie; Ueno, Takayuki; Lin, Ching-Hung; Liu, Qiang; Lee, Kyung-Hun; Leung, Roland; Naito, Yoichi; Park, Yeon Hee; Im, Seock-Ah; Li, Huiping; Yap, Yoon Sim; Lu, Yen-Shen (Breast cancer research and treatment, 2019)
Keywords: Age Factors; Antineoplastic Agents, Hormonal - administration & dosage; Antineoplastic Agents, Hormonal - adverse effects; Antineoplastic Agents, Hormonal - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Aromatase; Asian Continental Ancestry Group; Breast cancer; Breast Neoplasms - diagnosis; Breast Neoplasms - drug therapy; Breast Neoplasms - etiology; Cancer; Cancer research; Cancer therapies; Care and treatment; Chemotherapy; Clinical trials; Clinical Trials as Topic; Decision making; Epidermal growth factor; ErbB-2 protein; Evidence-based medicine; Female; Health risk assessment; Humans; Medicine; Medicine & Public Health; Menopause; Neoplasm Grading; Neoplasm Staging; Oncology; Ovarian cancer; Ovariectomy; Patients; Pituitary (anterior); Post-menopause; Postmenopausal women; Premenopause; Receptor, ErbB-2 - genetics; Receptor, ErbB-2 - metabolism; Receptors, Estrogen - genetics; Receptors, Estrogen - metabolism; Receptors, Progesterone - genetics; Receptors, Progesterone - metabolism; Reproductive status; Review; Risk groups; Tamoxifen; Treatment Outcome; Voting; Womens health; Ovarian suppression; Combined endocrine therapy; Treatment; Asia; Premenopausal breast cancer; CDK4/6 inhibitor